CN113453686B - 治疗眼表痛的方法 - Google Patents

治疗眼表痛的方法 Download PDF

Info

Publication number
CN113453686B
CN113453686B CN202080013685.7A CN202080013685A CN113453686B CN 113453686 B CN113453686 B CN 113453686B CN 202080013685 A CN202080013685 A CN 202080013685A CN 113453686 B CN113453686 B CN 113453686B
Authority
CN
China
Prior art keywords
compound
pain
use according
formula
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080013685.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113453686A (zh
Inventor
Q·梅德利
茂木宗人
M·蒙特奇-帕尔默
K·斯塔西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Ireland Ltd
Original Assignee
Bausch and Lomb Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch and Lomb Ireland Ltd filed Critical Bausch and Lomb Ireland Ltd
Publication of CN113453686A publication Critical patent/CN113453686A/zh
Application granted granted Critical
Publication of CN113453686B publication Critical patent/CN113453686B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080013685.7A 2019-02-15 2020-02-13 治疗眼表痛的方法 Active CN113453686B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806682P 2019-02-15 2019-02-15
US62/806,682 2019-02-15
PCT/IB2020/051210 WO2020165838A1 (en) 2019-02-15 2020-02-13 Methods for treating ocular surface pain

Publications (2)

Publication Number Publication Date
CN113453686A CN113453686A (zh) 2021-09-28
CN113453686B true CN113453686B (zh) 2025-04-15

Family

ID=69740423

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080013685.7A Active CN113453686B (zh) 2019-02-15 2020-02-13 治疗眼表痛的方法

Country Status (17)

Country Link
US (4) US20200261456A1 (https=)
EP (1) EP3923909A1 (https=)
JP (2) JP7571037B2 (https=)
KR (1) KR20210129677A (https=)
CN (1) CN113453686B (https=)
AU (2) AU2020222348B2 (https=)
BR (1) BR112021015998A2 (https=)
CA (1) CA3130038A1 (https=)
CL (1) CL2021002152A1 (https=)
IL (1) IL284629A (https=)
JO (1) JOP20210217A1 (https=)
MX (2) MX2021009702A (https=)
PH (1) PH12021551968A1 (https=)
SG (1) SG11202107260VA (https=)
TW (2) TW202515576A (https=)
WO (1) WO2020165838A1 (https=)
ZA (1) ZA202104593B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
WO2022029656A1 (en) * 2020-08-06 2022-02-10 Novartis Ag Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
CN119184616A (zh) * 2024-09-03 2024-12-27 中山大学附属第三医院粤东医院(梅州市梅县区人民医院) 一种疼痛等级的测评方法及其评估系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102281920A (zh) * 2009-01-13 2011-12-14 诺瓦提斯公司 用作辣椒素拮抗剂的喹唑啉酮衍生物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
US7893260B2 (en) 2005-11-04 2011-02-22 Hydra Biosciences, Inc. Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
BRPI0620264A2 (pt) 2005-12-22 2011-11-08 Prolexys Pharmaceuticals Inc quinazolonas aril-substituìdas e sua utilização
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
AR067631A1 (es) 2007-07-18 2009-10-21 Novartis Ag Combinaciones sinergicas de antagonistas de vr-1 e inhibidores de cox-2 , composicion farmaceutica y uso
TW200927192A (en) * 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
CA2707441A1 (en) 2008-01-09 2009-07-16 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009149239A1 (en) 2008-06-04 2009-12-10 Children's Medical Center Corporation Methods of modulating angiogenesis via trpv4
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
EP2316420B1 (en) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2390327A1 (en) * 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US9827225B2 (en) * 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
CN109790116B (zh) 2016-09-20 2022-10-28 葛兰素史密斯克莱知识产权（第2 号）有限公司 Trpv4拮抗剂
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
JP2022520410A (ja) * 2019-02-15 2022-03-30 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102281920A (zh) * 2009-01-13 2011-12-14 诺瓦提斯公司 用作辣椒素拮抗剂的喹唑啉酮衍生物

Also Published As

Publication number Publication date
AU2020222348A1 (en) 2021-08-05
BR112021015998A2 (pt) 2021-10-05
ZA202104593B (en) 2025-03-26
JP2022520832A (ja) 2022-04-01
JP2025004186A (ja) 2025-01-14
IL284629A (en) 2021-08-31
US20210275529A1 (en) 2021-09-09
TW202515576A (zh) 2025-04-16
CN113453686A (zh) 2021-09-28
PH12021551968A1 (en) 2022-05-23
JP7571037B2 (ja) 2024-10-22
TW202045179A (zh) 2020-12-16
WO2020165838A9 (en) 2021-03-18
KR20210129677A (ko) 2021-10-28
AU2023203716B2 (en) 2025-03-20
US20220193078A1 (en) 2022-06-23
MX2021009702A (es) 2021-09-14
SG11202107260VA (en) 2021-08-30
US20240342174A1 (en) 2024-10-17
TWI878266B (zh) 2025-04-01
MX2025000353A (es) 2025-02-10
EP3923909A1 (en) 2021-12-22
US11234982B2 (en) 2022-02-01
JOP20210217A1 (ar) 2023-01-30
WO2020165838A1 (en) 2020-08-20
AU2020222348B2 (en) 2023-03-16
CL2021002152A1 (es) 2022-04-18
US20200261456A1 (en) 2020-08-20
CA3130038A1 (en) 2020-08-20
AU2023203716A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
AU2023203933B2 (en) Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
AU2023203716B2 (en) Methods for treating ocular surface pain
RU2850452C2 (ru) Способы лечения боли на поверхности глаза
RU2853589C2 (ru) Составы на основе 4-(7-гидрокси-2-изопропил-4-оксо-4h-хиназолин-3-ил)-бензонитрила
KR20260057219A (ko) 4-(7-히드록시-2-이소프로필-4-옥소-4h-퀴나졸린-3-일)-벤조니트릴의제형

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20231126

Address after: Irish Dublin

Applicant after: Bausch & Lomb Ireland Ltd.

Address before: Basel, SUI

Applicant before: NOVARTIS AG

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant